...
首页> 外文期刊>Journal of Medicinal Chemistry >A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
【24h】

A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation

机译:用于诱导蛋白质降解的快速合成双特异性分子的“Click Chemistry平台”

获取原文
获取原文并翻译 | 示例

摘要

Proteolysis targeting chimeras (PROTACs) are bispecific molecules containing a target protein binder and an ubiquitin ligase binder connected by a linker. By recruiting an ubiquitin ligase to a target protein, PROTACs promote ubiquitination and proteasomal degradation of the target protein. The generation of effective PROTACs depends on the nature of the protein/ligase ligand pair, linkage site, linker length, and linker composition, all of which have been difficult to address in a systematic way. Herein, we describe a “click chemistry” approach for the synthesis of PROTACs. We demonstrate the utility of this approach with the bromodomain and extraterminal domain-4 (BRD4) ligand JQ-1 ( 3 ) and ligase binders targeting cereblon (CRBN) and Von Hippel–Lindau (VHL) proteins. An AlphaScreen proximity assay was used to determine the ability of PROTACs to form the ternary ligase–PROTAC–target protein complex and a MSD assay to measure cellular degradation of the target protein promoted by PROTACs.
机译:蛋白水解靶向嵌合体(PROTACs)是含有靶蛋白的粘合剂和通过接头连接的泛素连接酶粘合剂的双特异性分子。通过募集的泛素连接酶与靶蛋白,PROTACs促进靶蛋白的泛素化和蛋白酶体降解。的有效PROTACs产生依赖于蛋白质的性质/连接酶配体对,连接位点,接头长度,和连接器的组合物,所有这些都已经难以地址以系统的方式。在这里,我们描述了PROTACs合成的“点击化学”的做法。我们证明这种方法与溴基结构域和额外结构域-4(BRD4)配体JQ-1(3)和连接酶的粘合剂靶向cereblon(CRBN)和希佩尔 - 林道(VHL)蛋白的效用。一个的AlphaScreen邻近测定法是用来确定PROTACs以形成三元连接酶PROTAC靶蛋白复合物,以测量由PROTACs促进靶蛋白的细胞降解的能力和MSD测定。

著录项

  • 来源
    《Journal of Medicinal Chemistry 》 |2018年第2期| 共9页
  • 作者单位

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

    Department of Therapeutic Discovery?Discovery Technologies Amgen Inc. 1120 Veterans Boulevard South San Francisco California 94080 United States;

    Department of Therapeutic Discovery?Discovery Technologies Amgen Inc. 1120 Veterans Boulevard South San Francisco California 94080 United States;

    Department of Therapeutic Discovery?Discovery Technologies Amgen Inc. 1120 Veterans Boulevard South San Francisco California 94080 United States;

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

    Departments of Therapeutic Discovery?Medicinal Chemistry Oncology Research and Discovery Technologies Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320 United States;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号